Patents by Inventor Laxminarayan Joshi

Laxminarayan Joshi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sustained release metoprolol formulations
    Patent number: 10383832
    Abstract: The present invention relates to modified release pharmaceutical composition comprising metoprolol succinate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s). More specifically, the invention relates to modified release pharmaceutical compositions comprising metoprolol succinate and a process for preparation thereof.
    Type: Grant
    Filed: December 24, 2016
    Date of Patent: August 20, 2019
    Inventor: Laxminarayan Joshi
  • Sustained release metoprolol formulations
    Patent number: 9561187
    Abstract: The present invention relates to modified release pharmaceutical composition comprising metoprolol succinate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s). More specifically, the invention relates to modified release pharmaceutical compositions comprising metoprolol succinate and a process for preparation thereof.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: February 7, 2017
    Assignee: CMAX Technologies, Inc.
    Inventor: Laxminarayan Joshi
  • Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
    Publication number: 20090247603
    Abstract: The present invention is a new stable drug composition particularly suitable for use as an antihypercholesterolaemic or antihyperlipidaemic agent. The present invention is specifically a drug composition comprising a pharmaceutical, a complexing agent and a surfactant, and a method for manufacturing same. When applied to unstable drugs with low solubility and poor bioavailability, like HMG-CoA reductase inhibitors and especially atorvastatin calcium amorphous form, the resulting drug composition is more stable and is characterized by an improved dissolution profile.
    Type: Application
    Filed: December 23, 2005
    Publication date: October 1, 2009
    Applicant: Orbus Pharma, Inc.
    Inventor: Laxminarayan Joshi
  • STABILIZED EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING AN AMG-COA REDUCTASE INHIBITOR
    Publication number: 20080051448
    Abstract: The present invention is a new stable extended release drug composition particularly suitable for use as an antihypercholesterolaemic or antihyperlipidaemic agent. The present invention is specifically a drug composition comprising a pharmaceutical, a complexing agent and a matrix-forming agent, and a method for manufacturing same. When applied to acid-labile drugs like HMG-CoA reductase inhibitors, the resulting drug composition is stabilized and is characterized by an extended-release profile.
    Type: Application
    Filed: August 13, 2007
    Publication date: February 28, 2008
    Applicant: Orbus Pharma, Inc.
    Inventor: Laxminarayan Joshi
  • STABILIZED EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A BETA-ADRENORECEPTOR ANTAGONIST
    Publication number: 20070092573
    Abstract: The present invention is a new stable extended release drug composition particularly suitable for use as a beta-adrenoreceptor antagonist agent. The present invention is specifically a drug composition comprising a pharmaceutical, a methacrylic acid copolymer and a matrix forming agent, and a method for manufacturing same. When applied to highly soluble drugs like metoprolol succinate, the resulting drug composition is characterized by an extended-release profile.
    Type: Application
    Filed: October 23, 2006
    Publication date: April 26, 2007
    Inventors: Laxminarayan Joshi, Robert Lefler
  • Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
    Publication number: 20060229277
    Abstract: The present invention relates to pharmaceutical compositions containing an HMG-CoA reductase inhibitor which are protected from destabilization in acidic environments by utilizing an inclusion complexing agent, and further relates to their preparation and to their use in the treatment of hypercholesterolemia and hyperlipidemia.
    Type: Application
    Filed: April 8, 2005
    Publication date: October 12, 2006
    Applicant: Orbus Pharma, Inc.
    Inventor: Laxminarayan Joshi